BackDicerna Pharmaceuticals Overview

Dicerna Pharmaceuticals Receivables

Dicerna Pharmaceuticals's receivables is $6.2M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$6.23M
4.10% YoYΔ $245000.00 vs prior year quarter

Peer average

Loading

Dicerna Pharmaceuticals Receivables History

Loading

Dicerna Pharmaceuticals vs. peers: Receivables Comparison

Loading

Dicerna Pharmaceuticals Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Dicerna Pharmaceuticals (DRNA) FAQ

As of the most recent data (September 2021), DRNA shows a receivables of $6.2M. That compares with $6M in the prior-year period — up 4.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, DRNA's receivables is now $6.2M (was $6M) — a 4.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Dicerna Pharmaceuticals is outperforming or lagging.

Tracking DRNA's receivables over time shows whether Dicerna Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $6.2M That compares with $6M in the prior-year period — up 4.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Dicerna Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $6.2M) with ownership activity and broader fundamentals.

Dicerna Pharmaceuticals's receivables is $6.2M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.